# Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response

> **NCT02240888** · NA · COMPLETED · sponsor: **Region Skane** · enrollment: 300 (actual)

## Conditions studied

- RA
- SLE
- Vasculitis
- Scleroderma
- Sjögrens
- Syndrome

## Interventions

- **BIOLOGICAL:** 0,5 mg Prevenar i.m.
- **BIOLOGICAL:** 0,5 mg seasonal influenza vaccine i.m.

## Key facts

- **NCT ID:** NCT02240888
- **Lead sponsor:** Region Skane
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2017-12-31
- **Final completion:** 2018-05-31
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2018-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02240888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02240888, "Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02240888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*